Podcasts about Monty

Fantasy Football show for Mar 3, 2026. Free Agency preview and predictions! Plus, David Montgomery traded, Jahmyr Gibbs outlook, and other big NFL News! Andy, Mike, and Jason discuss which free agents and landing spots could have a major impact on 2026 fantasy football drafts! Manage your redraft, keeper, and dynasty fantasy football teams with the #1 fantasy football podcast. (00:00) Intro (05:20) Combine Takeaway (15:10) NFL News (41:00) Free Agent Predictions (43:45) Quarterback Predictions (47:50) Running Back Predictions (53:55) Wide Receiver Predictions (56:20) Tight End Predictions Connect with the show: Subscribe on YouTube Visit us on the Web Support the Show Follow on X Follow on Instagram Join our Discord Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

March 2nd, 2026 Follow us on Facebook, Instagram and X Listen to past episodes on The Ticket’s Website And follow The Ticket Top 10 on Apple, Spotify or Amazon MusicSee omnystudio.com/listener for privacy information.

HEADLINES: Texans get Monty/Chiefs cut Taylor/Uconn Women perfect again

On today's episode, everyone is fully medicated. We get 2 -- 3? -- cold opens because Ellyn is thirsty. Ellyn calls 2 gays and a Thermos. Daisy calls Kurt... and Monty. Abort mission! Act normal, not horny! Oh right, we're supposed to be talking about Love is Blind. Blahzayblah... Some couples get engaged. Ladies wear questionable shoes. But most importantly: THESE MEN ARE THE WOOOOORSSSSSST! We are all gravely concerned for the women of Ohio if this is the best Netflix could find. How was Chris even able to reach high enough to get that much audacity off the shelf? And who the fuck does Alex think he is? Daisy is going to write a strongly worded letter to Mr. Netflix, and Ellyn is going to submit an expense report to GBC for her anxiety meds.

Join us again for a trip to Alaska's wilderness. Our friends Monty Browning and Bryan Burkhardt were once again kind enough to record and share their 2025 Alaskan Moose hunt. With the 2025 deer season over, we are excited to bring their hunts to you. Their incredible day-to-day adventures are the things most of us only dream about. So set back and join them by the fire as they share another Alaskan Moose Adventure.

Join Debbie Loucks on a special episode of Horsemanship Radio.Each month, we'll delve into a chapter from Monty Roberts' insightful book, Horse Sense for People. Discover how Monty's revolutionary, non-violent communication techniques with horses offer invaluable lessons for human relationships, business, and personal growth. This series aims to share Monty's timeless wisdom and inspiring stories with everyone, free of charge. Tune in on the 1st and 15th of every month for new episodes of Horsemanship Radio!Horsemanship Radio 298:Show Host: Debbie LoucksTitle Sponsor: HandsOn Gloves, All-In-One Shedding/Bathing/Grooming GlovesPhotos used with permissionPurchase your own copy of Horse Sense for PeopleLearn more about Good Horsemanship at Monty Roberts EQUUS Online University Monty's CalendarPlease follow Monty Roberts on FacebookFollow Monty Roberts on Twitter or on InstagramSee more at: MontyRoberts.comHear all the shows on the Horse Radio NetworkSupport the show

Today's Show: WHEN PEOPLE DON'T LIKE YOU. In this short Montyman's Meditorial, Monty shares some helpful tips on how to respond to those who may be less than kind when interacting with you. There is a way to keep your dignity and peace even around folks that don't like us. #recovery #alcoholic #twelvesteps #wedorecover #addiction 

Soly, Neil and Tron have searched far and wide for rules controversies from recent, and not so recent, golf history.  Enjoy this look at some of our favorites including Tiger's drop on 15 at Augusta in 2013 as well as some dust ups involving the Walrus, Monty, Arnie and Brooks. Plus - of course - TC's extensive list of other possible infractions we'll save for another day. Timestamps 0:00 - Intro 5:10 - Tiger's drop at the 2013 Masters 34:15 - 1987 Craig Stadler TowelGate 1:01:30 - Monty's Jakarta incident 1:13:05 - Arnie at the 1958 Masters 1:34:45 - Brooks at the 2023 Masters Show Notes: Golf Digest Video on the 2013 Tiger Drop Join us in our support of the Evans Scholars Foundation: ⁠⁠⁠⁠https://nolayingup.com/esf⁠ Support our Sponsors: Titleist Rhoback Lagoon If you enjoyed this episode, consider joining⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ The Nest⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠: No Laying Up's community of avid golfers. Nest members help us maintain our light commercial interruptions (3 minutes of ads per 90 minutes of content) and receive access to exclusive content, discounts in the pro shop, and an annual member gift. It's a $90 annual membership, and you can sign up or learn more at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠nolayingup.com/join⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Subscribe to the No Laying Up Newsletter here: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://newsletter.nolayingup.com/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Subscribe to the No Laying Up Podcast channel here: https://www.youtube.com/@NoLayingUpPodcast Learn more about your ad choices. Visit megaphone.fm/adchoices

Roland Cox is the founder and creator of the Daddy Builders Network. Daddy Builders Network is designed to give Daddies hope, encouragement, information, strategies, and ideas to equip them to become and remain active in the lives of their children.   Roland is married to Michelle, and they've been married 13 years (been together for 20 years). And together they have two children, Makayla (14) and Monty (11). And they've raised Destiny, Roland's 22 year-old daughter, for the past 11 years.   To contact Roland Cox, visit his website at http://www.DaddyBuildersNetwork.org or email him at info@daddybuildersnetwork.org    ----------------------     Talk with Dr. Joe 1-on-1: Are you tired and stuck? Want to go to get your faith, marriage, family, career and finances back on track?  Then maybe it's time you got a coach. Every CHAMPION has one. Schedule an appointment to chat with Dr. Joe. He takes on only a few Breakthrough Calls each week.  The call is FREE, but slots are limited to ONE call only.  NO RESCHEDULES.  Just click on the link below and select the BREAKTHROUGH CALL option to set up an appointment: http://TalkwithDrJoe.com  If no slots are available, please check back in a week.   Also join us on: Online Podcast Community (on Station):  https://station.page/realmen Facebook: @realdrjoemartin YouTube: http://www.RealMenTraining.com Instagram: @realdrjoemartin Twitter: @professormartin Website: https://RealMenConnect.com

(00:00-10:41) Spread Zone & QFTA today. Jackson's hard out at 3. Nice sentiment from Lisa. Ketchup talk. Husband and wife broadcast team on ESPN+ last night. Chairman's throwing a birthday party for his dog today and invited JR but not the rest of the crew. A dog cake. They just don't like to see people happy.(10:49-28:06) Friend of the show and former Billiken, Ryan Luechtefeld joins the show. What does he think is going on with the Billikens' recent struggles? Time for Thames to start. People getting on board with this year's team more so than years past. Is it time for the Billikens to head to the Big East? Beating UMass in the opening round of the tournament in '98 before getting beat by Kentucky. SLU & Mizzou.(28:16-36:32) The Design Aire Heating & Cooling E-Mail of the Day. Robert Thomas taking a personal leave of absence from the Blues. Nothing to do with the deadline and not trade related.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Red Wings trade talk, Irrational fears, Monty's role.

David Montgomery.

Big Lions news.

Do you want Monty back?

This week, we kick off with a bit of Fire Horse chat with a side of wtichy wog curse energy, which Mel's mad for, but Monty isn't buying in to. We chat about the a Sydney guy's attempt to bring back the rave with a MAJOR twist on the ones we grew up with in the 90s. Speaking of, one half of an Aussie couple who was rarely seen without her leotard back in the day triggered a memory for aerobics queen Monts, and something revolting happened to Mel when she was jazzing up her jewellery. Enjoy! Fancy supporting us on Patreon? Find out more here. Follow us and get in touch on Instagram here. Follow us on Facebook here.See omnystudio.com/listener for privacy information.

Peter Caddick-Adams is a lecturer in military history and current defense issues at the UK Defence Academy. He is the author of Monte Cassino: Ten Armies in Hell and Monty and Rommel: Parallel Lives. He holds the rank of major in the British Territorial Army and has served with U.S. forces in Bosnia, Iraq, and Afghanistan.

Furf and Monty are back with another Pulm PEEPs Pearls episode. The topic of today’s discussion is an often discussed, but often misunderstood, test; the methacholine challenge. They’ll review when to utilize this test, how it should be performed, and the appropriate interpretation. Contributors This episode was prepared with research by Pulm PEEPs Associate Editor George Doumat. Dustin Latimer, another Pulm PEEPs Associate Editor, assisted with audio and video editing. Key Learning Points What the Test Measures Methacholine challenge is a direct bronchial provocation test of airway hyperresponsiveness (AHR), a core physiologic feature of asthma. Anyone will bronchoconstrict at high enough concentrations — the test looks for an abnormal threshold. The key endpoint is the PC20: the methacholine concentration causing a 20% fall in FEV1. Abnormal in adults: PC20 ≤ 8–16 mg/mL Test Performance Meta-analyses: pooled sensitivity ~60%, specificity ~90%. Real-world cohorts: sensitivity 55–62%, specificity 56–100% (varies by population, protocol, and threshold used). Not a standalone yes/no test — best used as part of a broader diagnostic pathway. Where It Fits in the Asthma Workup The test belongs in a stepwise approach: Step 1: Spirometry + bronchodilator response Step 2: Add FeNO and/or peak flow variability (if available) Step 3: If the picture is still unclear → methacholine challenge It is most useful for symptomatic patients with normal spirometry and no bronchodilator reversibility. Given its cost, mild risk, and discomfort, it should not be a first-line test — most asthma diagnoses do not require it. Technique and Medication Prep Technique ERS guidelines favor tidal breathing over deep inspiratory maneuvers. Deep breaths can be bronchoprotective and blunt the response, reducing sensitivity — especially in mild or well-controlled asthma. Medication Washout (to Avoid False Negatives) Medication ClassWashout PeriodShort-acting beta-agonists (SABA)≥ 6 hoursLong-acting beta-agonists (LABA)~24 hoursUltra-long-acting beta-agonists~48 hoursShort-acting anticholinergics (e.g., ipratropium)~12 hoursLong-acting muscarinic antagonists (LAMA, e.g., tiotropium)7 days Inhaled corticosteroids, leukotriene blockers, and antihistamines do not significantly affect the test acutely — continue these. Withdrawing ICS also carries its own risk for asthma patients. Practical tip: Spell out exactly what to hold and when — for both the patient and the PFT lab — at the time the test is ordered. Interpreting Results Negative Test (PC20 > 16 mg/mL) Very high negative predictive value in symptomatic adults. Makes current asthma quite unlikely (assuming proper test conduct). This is the test’s greatest strength: it is an excellent rule-out test. Positive Test (PC20 ≤ 8–16 mg/mL) More nuanced — airway hyperresponsiveness is not unique to asthma. Can be positive in: chronic cough, allergic rhinitis, COPD, and even some healthy asymptomatic individuals. A positive result raises probability but must be interpreted alongside the clinical story, variable respiratory symptoms, peak flow variability, FeNO, and ICS response. Safety and Risks Overall, the test is quite safe; significant adverse effects are rare. Temporary breathing discomfort is expected (bronchoconstriction is being induced). Severe bronchospasm is possible: A trained clinician should be available; SABA inhaler/nebulizer must be immediately on hand; a physician should be reachable in the facility. Contraindications / cautions: Avoid if FEV1 < 70% predicted or < 1–1.5 L (baseline obstruction greatly increases risk). Avoid within 3 months of an acute cardiac event (rare risk of cardiac events with unstable cardiac disease). Five Pearls — Quick Recap What it tests: Methacholine challenge is a direct test of AHR with high specificity but variable sensitivity — it belongs inside a diagnostic pathway, not as a standalone asthma test. When to use it: Most useful for symptomatic patients with normal spirometry and no bronchodilator response, after FeNO and peak flow variability have been considered. Technique and meds matter: Use tidal breathing protocol; respect washout intervals — especially the 7-day LAMA washout and 24–48 hour LABA window — to avoid false negatives. Safety: Generally safe, but can induce significant bronchoconstriction. Have a SABA available and avoid the test in patients with FEV1 < 70% predicted. Interpretation: A negative test (PC20 > 16 mg/mL) strongly argues against current asthma. A positive test raises probability but is not specific — interpret alongside the full clinical picture. References and Further Reading Coates AL, Wanger J, Cockcroft DW, Culver BH; Bronchoprovocation Testing Task Force: Kai-Håkon Carlsen; Diamant Z, Gauvreau G, Hall GL, Hallstrand TS, Horvath I, de Jongh FHC, Joos G, Kaminsky DA, Laube BL, Leuppi JD, Sterk PJ. ERS technical standard on bronchial challenge testing: general considerations and performance of methacholine challenge tests. Eur Respir J. 2017 May 1;49(5):1601526. doi: 10.1183/13993003.01526-2016. PMID: 28461290. Lee, J., & Song, J. U. (2021). Diagnostic comparison of methacholine and mannitol bronchial challenge tests for identifying bronchial hyperresponsiveness in asthma: a systematic review and meta-analysis. Journal of Asthma, 58(7), 883–891. https://doi.org/10.1080/02770903.2020.1739704 Davis BE, Blais CM, Cockcroft DW. Methacholine challenge testing: comparative pharmacology. J Asthma Allergy. 2018 May 14;11:89-99. doi: 10.2147/JAA.S160607. PMID: 29785128; PMCID: PMC5957064.

GAME TIME! Star Wars RPG Session #39 Episode 39: The Speed of a Spark Our Heroes have begun work on their totally legal and upstanding business venture, a space-road truck stop station called Bugg-Notts or Lil Wooks (name still pending) along the Shipping lanes of Polis Massa; while our mighty adventurers are bedazzling a duck and leather punching around Bespin, they smooth talk their way to begin co opting local talent finding a great staff capable of serving more than meets the eye. Quickly recruiting an Ithorian bartender: Mon'Tau, or Monty or Muadib, the name was lost millions of years ago...Yudex and his constant pursuit of velocity, inspires the crew to join in the local space races and Edna, in a shocking twist, gifts Yudex a shiny new A-wing and the team updates the lean machine for the win! Yudex is able to pilot his way to a thrilling victory across the finish line and into the hearts of locals. Our wild bunch of heroes begin recruiting pilots for the Rebellion! With promise of food and glory, a new group of recruits, a collection of potatoes, and SCR-V creating a secret droid underground, the genesis of DLF, the Droid Liberation Front for Intel, it's time to return to Polis Massa to begin negotiations to begin building a new home. Now for the continuing Saga of FSF's Star Wars RPG!!! ROLL FOR INITIATIVE! Follow our gamers on Threads and Instagram - Sam from Growing Up Skywalker - @growingupskywalker Casey Plott - @Plottimus21 Ben Reilly - @hearty_healer Kathleen - @kathleenfwass GM John - @athair_honora Tim - @pcapodshow Pop Culture Addicts Theme song "Racing in Darkness" by Nautilus '54 - https://nautilus54.bandcamp.com/album/the-fell-star-2 For more on our show partners - Level Up Sabers - https://bit.ly/LevelUpFSF Once Upon a Tee - https://www.onceuponatree.net/?ref=pcapod Sign Up for Free Loot here - www.pcapod.com/contact For more on our Show - Join our Patreon: https://www.patreon.com/c/popcultureaddicts Join our Discord! https://discord.gg/cpry4fCDTq Visit our website: https://www.pcapod.com PCA on Instagram, and Threads - @pcapodshow This podcast is powered by Pinecast.

GAME TIME! Star Wars RPG Session #39 Episode 39: The Speed of a Spark Our Heroes have begun work on their totally legal and upstanding business venture, a space-road truck stop station called Bugg-Notts or Lil Wooks (name still pending) along the Shipping lanes of Polis Massa; while our mighty adventurers are bedazzling a duck and leather punching around Bespin, they smooth talk their way to begin co opting local talent finding a great staff capable of serving more than meets the eye. Quickly recruiting an Ithorian bartender: Mon'Tau, or Monty or Muadib, the name was lost millions of years ago...Yudex and his constant pursuit of velocity, inspires the crew to join in the local space races and Edna, in a shocking twist, gifts Yudex a shiny new A-wing and the team updates the lean machine for the win! Yudex is able to pilot his way to a thrilling victory across the finish line and into the hearts of locals. Our wild bunch of heroes begin recruiting pilots for the Rebellion! With promise of food and glory, a new group of recruits, a collection of potatoes, and SCR-V creating a secret droid underground, the genesis of DLF, the Droid Liberation Front for Intel, it's time to return to Polis Massa to begin negotiations to begin building a new home. Now for the continuing Saga of FSF's Star Wars RPG!!! ROLL FOR INITIATIVE! Follow our gamers on Threads and Instagram - Sam from Growing Up Skywalker - @growingupskywalker Casey Plott - @Plottimus21 Ben Reilly - @hearty_healer Kathleen - @kathleenfwass GM John - @athair_honora Tim - @pcapodshow Pop Culture Addicts Theme song "Racing in Darkness" by Nautilus '54 - https://nautilus54.bandcamp.com/album/the-fell-star-2 For more on our show partners - Level Up Sabers - https://bit.ly/LevelUpFSF Once Upon a Tee - https://www.onceuponatree.net/?ref=pcapod Sign Up for Free Loot here - www.pcapod.com/contact For more on our Show - Join our Patreon: https://www.patreon.com/c/popcultureaddicts Join our Discord! https://discord.gg/cpry4fCDTq Visit our website: https://www.pcapod.com PCA on Instagram, and Threads - @pcapodshow This podcast is powered by Pinecast.

The boys are back to discuss the latest in the EIHL, including the weekend games, what's going on in Fife, the panels all time PP line and much more.

Sermon Notes Date: 02/22/2026 Preacher: Monty Simao, pastor Study: Matthew Key Text: Matthew 1:18-25 Description: A virgin conceives. A righteous man trembles. An angel speaks. And everything changes. Today on Scandia Bible Church Podcast, Pastor Monty Simao continues our study through the Gospel of Matthew — where we are pressed to consider whether the greatest […]

Send a textIn this third season, I am sharing chapters from my short novel “Zunzuncito's Adventure”. This week is chapter 5! Zunzuncito is done dealing with the small life. He wants to be big. Luckily, his new frog friend Monty knows about a special magic flower that might be able to grant his wish. He just doesn't know where it is. So, the hummingbird and frog head to the woods in search of the all-knowing Majá. On the way, Zunzuncito learns a few things about his small amphibious friend.This story is told in the the present tense. Repeated words and phrases include frog, forest, trees, ground, jump and fly. No matter where you are in your language journey, stories will help you on your way. You can find a transcript of the story and read along at https://smalltownspanishteacher.com/2026/02/23/simple-stories-in-english-zunzuncitos-adventure-chapter-5/ Thank you for listening, and a HUGE thank you for your support. I really enjoy creating and sharing simple, comprehensible stories. If you would like to help me in that endeavor, consider donating to @Small Town Spanish Teacher on Venmo, PayPal, or Buy Me A Coffee https://www.buymeacoffee.com/SpanishTeacher .

To support this ministry and help us continue to reach people all around our region, click here: http://bethel.ag/give/Stay Connected Website: www.bethel.ag Bethel Church Facebook: www.facebook.com/bethelchurch605/ Bethel Church Instagram: www.instagram.com/bethelchurch605/

Join us again for another trip to Alaska's wilderness. Our friends Monty Browning and Bryan Burkhardt were once again kind enough to record and share their 2025 Alaskan Moose hunt. With the 2025 deer season over, we are excited to bring their hunts to you. Their incredible day-to-day adventures are the things most of us only dream about. So set back and join them by the fire as they share another Alaskan Moose Adventure.

http://montysrockcast.com/wp-content/uploads/2026/02/Rockcast289.mp3 On this February episode, Monty talks about the Grammys, the Superbowl, hackers, and the all-time greatest rockstars. He also answers lots of Listener questions and emails and gives you a sample of a new Galactic Cowboys song!

Episode 591! It's WWE Royal Rumble! James, Monty and Gina are here for all things WWE! We have Raw and Smackdown Catch Up then the event itself! Plus lot's more! Enjoy!!

Monty and Mickey continue covering the IT universe with IT: Welcome to Derry (season 1). Enjoy!

The Moneywise Radio Show and Podcast Thursday, February 19th BE MONEYWISE. Moneywise Wealth Management I "The Moneywise Radio Show & Podcast" call: 661-847-1000 text in anytime: 661-396-1000 website: www.MoneywiseGuys.com facebook: Moneywise_Wealth_Management LinkedIn: Moneywise_Wealth_Management Guest: Monty Byrom and Paul South of, "Buddha's Beef"  Bands Website: https://buddhasbeefandmeatpacking.com/ Tickets to Saturday's Show: An Evening with Buddha's Beef  The opinions voiced in this podcast are for general information only and are not intended to provide specific advice or recommendations for any individual. To determine which strategies or investments may be suitable for you, consult the appropriate qualified professional prior to making a decision.  

Monty, Nick, and Dom Listi talk the first midweek madness of the season, preview weekend two, and provide their X-Factors.

Dr. Monty Pal and Dr. Ari Rosenberg discuss the evolution of treatment strategies in head and neck cancers, including the challenges of treating both HPV-positive and HPV-negative disease and the emergence of blood-based biomarkers to advance personalized therapy across different subtypes. TRANSCRIPT Dr. Monty Pal: Hello and welcome to the ASCO Daily News Podcast. I'm your host, Dr. Monty Pal. I'm a medical oncologist, professor, and vice chair of academic affairs at the City of Hope Comprehensive Cancer Center in Los Angeles. Today, we're going to explore the evolving landscape of treatment strategies in head and neck cancer management, including locoregionally advanced head and neck squamous cell carcinoma, which happens to be on the rise in United States, in part due to spike in HPV-mediated oropharyngeal cancers. We're also going to discuss the emerging strategies of using blood-based biomarkers to really advance personalized therapy. Joining me for this discussion is Dr. Ari Rosenberg. He's a medical oncologist focused on head and neck cancer, and he's an associate professor – congratulations on the recent promotion – at the University of Chicago. The University of Chicago has really produced luminaries in this field, Dr. Rosenberg included. I've had the pleasure of getting to know Dr. Ezra Cohen over the years, who really had his grounding there, and of course Everett Vokes, former ASCO President. I'm really looking forward to this conversation, Ari. Thanks so much for joining us. Dr. Ari Rosenberg: Thanks, Monty. Thanks for the invitation. Dr. Monty Pal: You got it. And just a quick note for our listeners, our full disclosures are going to be in the transcript at the end of this episode. So let's start with the basics, if you don't mind. So, head and neck cancers are very diverse and they're challenging, right? In the sense that they're near vital organs, the treatments, you know, as we all saw during fellowship, if not now in clinical practice. They can really have such a major impact on vital organ function, speech, swallowing, et cetera. Can you just comment on head and neck cancers that are on the rise in the U.S.? I alluded to this briefly. Particularly, we've heard this in the context of colorectal cancer and so forth. Are you actually seeing younger adults being affected by this? Dr. Ari Rosenberg: Yeah, thanks for that. The vast majority of head and neck cancers are head and neck squamous cell carcinomas, as I'm sure many of the listeners recall as well from fellowship or their current training. And as you alluded to, the organ function, long-term and functional quality of life outcomes are quite important, particularly in the context that these develop in high value real estate, parts of our head and neck area that we use for speaking, swallowing, all sorts of other essential functions as well. As you also alluded to, we think of this in two different particular subtypes of head and neck cancer. The historical head and neck cancer from 50, 60 years ago was almost exclusively related to carcinogen exposure, tobacco, alcohol use, and that subtype of carcinogen-induced head and neck cancer has been slowly declining. However, over the last now several decades, we've been seeing an increase in primary oropharyngeal squamous cell carcinoma, mostly tonsil, base of tongue. These are attributable to HPV, human papillomavirus exposure. And that's now the majority of the head and neck cancers that we tend to see in our clinic. As you also alluded to, these have very different prognoses as well. HPV-related head and neck cancer has a much more favorable prognosis where much of the interest has been in can we de-intensify to optimize long-term function? But then the non-HPV-related head and neck cancer, or what we call HPV-negative head and neck cancer, continue to be very, very challenging. We only managed to cure about half of these folks, with many of these patients developing the current disease. These patients, in addition to being difficult to treat, also have major impacts both in terms of the treatments they undergo as well as their disease that can impact their function and quality of life. And you hinted at this a little bit, but we have been seeing an increase in younger patients with HPV-negative head and neck cancer as well, which is quite concerning. Younger patients, oftentimes never smokers, never drinkers, who are developing non-HPV-negative head and neck cancer. And that's been a little bit of a more recent trend that we've been seeing as well. So, definitely a lot of work to be done to optimize and improve outcomes across all of these different head and neck cancer subtypes. Dr. Monty Pal: I mean, I'm just curious, you know, in the context of colorectal cancer, one of the things that we talk about is the potential role of the microbiome driving some of these young-onset cancers with, you know, perhaps there being an impact on, for instance, inflammation and the gut and what have you. Tell me about head and neck cancer. Is this anything known as to why younger patients might be getting diagnosed with non-HPV type cancers? It's odd to me. Dr. Ari Rosenberg: Yeah, it's a great question. A lot of people are working on it. I think we folks have hypotheses, but it hasn't totally panned out exactly what's going on there. It does have a little bit more of a tendency towards women, whereas historically head and neck cancer is much more common in men than it is in women. But lots of people working on that, whether it's related to chronic inflammation, whether it's related to the microbiome. Whether it's related to dental exposure, dental work. So, a lot of folks trying to parse that out because I agree with you, it needs to be identified alongside improving treatment paradigms for these patients, the young ones and the older patients as well. Dr. Monty Pal: Interesting, interesting. You know, one of the phenomena that was sort of coming around when I was in training 25 years ago was this role of sort of induction therapy for head and neck cancers. And of course, it's really come full circle now to include checkpoint inhibitors and so forth. Tell me a little bit about this and how you apply it, maybe in an HPV-mediated context, maybe in a non-HPV context. Dr. Ari Rosenberg: Yeah, absolutely. Induction chemotherapy, as you alluded to, or neoadjuvant chemotherapy, depending on what the locoregional treatment approach is. Similar to other cancer types where systemic control early on has many potential advantages in this setting. Now, in head and neck cancer, even though induction chemotherapy is quite active in head and neck cancer, both HPV-positive and HPV-negative with pretty good response rates. A survival advantage for all comers with local regionally advanced disease remains unproven. There's been two randomized trials, both underpowered, but essentially did not show a survival advantage, showing that induction chemotherapy for all patients with locoregionally advanced and neck cancer can't be justified for a survival advantage. That being said though, there remains a number of potential advantages of giving induction or neoadjuvant chemotherapy, of course, improving systemic control and debulking the disease early on has potential advantages, and predicting the responsiveness to subsequent radiation treatment. We know for some time in head and neck cancer that the percentage of shrinkage or the response to induction chemotherapy actually predicts outcome related to radiation as a dynamic biomarker where response can be used to select patients, for example, for de-escalated radiation has been an area of active investigation, active research. And it also remains a key opportunity to evaluate predictive biomarkers and understanding pre and post treatment to better understand the biology. I'll just add to your question that recently over this past year, we also saw phase 3 data for neoadjuvant immunotherapy for a subset of head and neck cancer that is surgically resectable. And so that's reintroducing the potential benefit in the immunotherapy era of incorporating immunotherapy in the neoadjuvant or the induction setting as part of the evolving treatment paradigm for these diseases. Dr. Monty Pal: That's really interesting. And you kind of alluded to already several topics that I plan to hit on, you know, for instance, the role of immune checkpoint inhibitors, induction, chemotherapy, and so forth. And you started to touch on biomarkers. And of course, I think that's something near and dear to many of us in academic oncology. One thing that we've started talking a lot about in the context of colorectal cancer is circulating tumor DNA. How do you think this might fit in the context of head and neck cancer? Can you give us a flavor for that? Dr. Ari Rosenberg: Yeah, absolutely. In head and neck cancer, the current landscape is most developed for circulating tumor DNA for HPV-related head and neck cancer. The advantage of HPV-related head neck cancer is that you have a distinctive HPV DNA that does tend to spill out into the peripheral blood and can be detected using various different blood-based assays. And because of that advantage as a tissue agnostic approach, it turns out that a number of HPV DNA plasma assays are actually quite sensitive and quite specific. And a number of them have indeed been commercialized. Of course, not only for detecting a baseline, but also grading responsiveness during treatment and probably most importantly in the post-treatment surveillance setting, the detection of HPV DNA in the plasma remains a very important and substantial predictor of developing recurrent disease. There's been a number of trials that have been emerging looking at ctDNA and HPV-related head and neck cancer, using it, for example, as a strategy to deescalate patients. That was something we saw this past ASCO from the Dana-Farber group, and also using it to early detect recurrence and potentially intervene earlier for patients with minimal residual disease positivity. So, that remains evolving and as many folks are, I think, already using it in the clinic. But ctDNA also has a lot of potential for HPV-negative head and neck cancer. This is actually a bit more challenging to develop because you don't have that HPV DNA that you can track predictably because the tumor is an HPV- negative disease are much more heterogeneous, but there are a number of data that are coming out both for personalized assays such as Signatera or some of the other assays that require tumor. Unlike colon cancer, which you referenced, where most patients get surgery upfront, in head and neck cancer, many of the patients receive non-surgical pre-chemoradiation. So sometimes the amount of tumor available to generate a personalized assay is more limited and can be one of the challenges that we see in head neck cancer. But certainly that also seems to be emerging. And there's also further assays that are being developed for HPV-negative head neck cancers, such as methylomic signatures and others that may be tissue informed or tissue agnostic. And these are also emerging, particularly in the post-treatment surveillance setting as strong predictors of recurrent disease. So while we're certainly behind some of these other more common tumor types, colon cancer, lung cancer, we're right there with them and more and more trials are going report out, including a number of trials in our upcoming [University of Chicago] Head and Neck Cancer Symposium where I'll be presenting some data and others in the field will be presenting some data looking at ctDNA both for HPV-positive and for HPV- negative to try to improve outcomes for these patients. Dr. Monty Pal: That's so interesting. I've got to tell you that in kidney cancer, what I deal with day to day is a very low shedding disease, right? So techniques as opposed to ctDNA looking for tumor-informed information, that might be less preferred to something like methylomics where you might not necessarily be so contingent on what's happening in the primary tumor. I'm really interested in you mentioning that. Just a point of clarification, this is something I'm trying to wrap my head around. You'd mentioned circulating tumor HPV DNA, right? I assume this is markedly different from just looking for HPV titers in the patient, right? So is this actually incorporated elements of HPV within, you know, essentially host genome, if you will? Dr. Ari Rosenberg: Yeah, correct. This is circulating tumor HPV DNA. And we think of it biologically as a plasma-based tumor DNA biomarker that's specific for HPV-related head and neck cancers. Dr. Monty Pal: Got it, got it. It makes me wonder whether or not this might be applicable to diseases like cervical cancer and so forth where there's also extensively, you know, biology driven by HPV. Is that fair? Dr. Ari Rosenberg: Yes, definitely. And in the head and neck cancer field, much of this ctDNA actually was derived from a different viral mediated head neck cancer, is less common in the U.S., but nasopharyngeal cancer, which is oftentimes associated with EBV. That has been a biomarker for quite some time in nasopharyngeal cancer. Of course, in places where EBV-associated nasopharyngeal cancer, is endemic, such as East Asia, this has been around for quite some time, but we've been using that in the U.S., and there's been trials that have used EBV DNA plasma to predict recurrence and stratify for adjuvant treatment, for example. And so now with HPV, it's much more applicable to our US population because the vast majority of our head and neck cancer patients that we see in the US that are viral mediated in the US tend to be HPV-related. So having assays that we can use to improve outcomes for that biological subset remains of particular interest for us. Dr. Monty Pal: Yeah, that's fascinating. By the way, for the fellows listening, there's tons of boards pearls here that Dr. Rosenberg shared, EBV-associated cancers, the role of HPV and treatment association. So if you're recertifying anytime soon, I definitely think there's notes to take from this conversation indeed. I wanted to shift gears a little bit. And obviously, you're a prolific researcher. I don't think anyone goes through their fellowship in medical oncology without recounting these experiences of our head and neck patients really suffering from treatment-related toxicities. It's a real challenge. And I'm just wondering, I know a big body of work that you're focused on is really using multimodality treatment paradigms to perhaps reduce the cumulative treatment burden of patients with head and neck cancers. Can you talk about that a little bit? Dr. Ari Rosenberg: Yeah, definitely. Thanks for the question. And before I start going into some of the strategies, I'll just say that head and neck cancer, this is particularly for the fellows that are listening as well, just in reference to your prior comment, that this is really a multidisciplinary disease. At our center, all head and neck cancer patients are seen upfront at that first visit by all three specialties, med onc, rad onc, and surgery, because the choice and sequencing of modalities to optimize not only survival, but also functional quality of life outcome is so critical. And I think that's probably the biggest takeaway for anyone who treats a lot of head and neck cancer or will be treating a lot of head and neck cancer in the clinic. But in terms of more specific attempts at trying to optimize some of those parameters that you described, we really think about these separately in terms of HPV-positive and HPV-negative head and neck cancer. For HPV-positive head and neck cancer, the cure rates are quite high with chemo radiation, although not for everyone. There's still about 15, 10 to 15 % of folks that will develop a recurrence. But for the vast majority of patients, standard chemoradiation is quite a cure to therapy, but the toxicity associated with that can be quite substantial. And so there's been a number of attempts to try to deescalate treatment. It turns out that deescalating everyone with locoregionally advanced HPV-positive head and neck cancer is not a good strategy because it's not able to select out the patients that really do need full dose treatment. And we have seen some negative trials that show inferior outcomes when everyone is deescalated. But what does remain promising is again, trying to select out who the best candidates are for deescalated treatment. The folks at MSK have hypoxia imaging that they're using in trials that looks quite promising to select for the more favorable deescalatable biology. At our center, we've been interested in using induction chemotherapy to stratify response and select patients for deescalated treatment with excellent survival outcomes and reduce toxicity with deescalated treatment. And more recently, ctDNA that us and other groups, such as the Dana-Farber group, is using. And that also looks quite promising. Again, how do you select the patient who will do well with less radiation versus the ones that really need the full doses and volumes of radiation? And then for HPV-negative head and neck cancer, this is a much trickier disease because already the survival outcomes are not like we want it to be. Trying to figure out how to improve survival outcomes remains an important thing. Using immunotherapy seems to be one of the key cornerstones to that. But these are patients that also suffer from a lot of toxicity related to their treatment. We completed a trial not too long ago that we published this past year where we, in HPV-negative head and neck cancer patients, de-intensified the radiation for responders to neoadjuvant chemoimmunotherapy. And those patients did similar, if not even a little bit better, than the non-responders who got full dose treatment. So something that does warrant further investigation as well. How do we not only improve survival for those patients, but also reduce some of the long-term toxicities? Dr. Monty Pal: This is brilliant. I'm taking so many notes as you were mentioning these items. There are so many areas where I think the research crosses over. I already mentioned, know, ctDNA, for instance, and metabolomics and the places where that might apply to kidney cancer. The hypoxia imaging really caught my ear too. Obviously, kidney cancer is disease highly predicated on hypoxia. So thank you for all of this. We've got about a minute or so. So, I'm going to ask you for a really tall task here. Can you tell us what you foresee being some of the biggest challenges that sort of lie ahead and head and neck cancer. You've already kind of alluded to it with ongoing research, but if you had to pick maybe 2, 3 problems, the very most that we really need to get to and head and neck cancer, what would that be? Dr. Ari Rosenberg: Yeah, that's a great question. Obviously, lots of things to be done, but if I'm going to limit it to just a couple, I would say number one is really trying to improve the survival for HPV negative local regionally advanced head and neck cancer. We talked early on about how we are seeing, you know, of course we see many of these people that were smokers and drinkers, but also seeing these in younger patients, in patients without a history of tobacco use. Some of these are very biologically aggressive and we need better treatments beyond surgery, beyond chemo radiation, beyond immunotherapy to improve outcomes for these patients and cure more of them. So, I would say that's one big area. And the other is, which we didn't speak about so much in this talk, but remains one of the biggest challenges that we see in the clinic is the recurrent metastatic head and neck cancer patients. This is an incredibly challenging disease to treat, not only with poor survival, but also with substantial impacts on quality of life and function. mean, these are bad recurrences that cause a lot of pain, functional deficits, really impacts quality of life as well. So developing novel therapies, many of which are currently in clinical trials and many of which are currently continuing to be developed, remains so critical. How do we develop better systemic therapies, better targeted therapies, better biomarkers for recurrent metastatic head neck cancer to improve their survival and quality of life and functional outcomes. Those are the two big areas that require the most work at this time within the head and neck cancer field. Dr. Monty Pal: That's brilliant. I mean, I have to tell you I could probably talk to you all day about this, such a fascinating topic. It's a very exciting time in the field. Thank you, Dr. Rosenberg, for all your incredible contributions and thanks for sharing with us your insights on the ASCO Daily News Podcast. Dr. Ari Rosenberg: Yeah, and thanks for the introduction. Hope to do it again soon. Dr. Monty Pal: And many thanks to our listeners for your time today. If you value the insights that you hear from the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. More on today's speakers:      Dr. Monty Pal   @montypal  Dr. Ari Rosenberg @AriRosenbergMD Follow ASCO on social media:           ASCO on X     ASCO on Bluesky          ASCO on Facebook           ASCO on LinkedIn           Disclosures:        Dr. Monty Pal:       Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview      Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical      Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis  Dr. Ari Rosenberg:     Stock and Other Ownership Interests: Privo Technologies Consulting or Advisory Role: Nanobiotix, EMD Serono, Vaccitech, Novartis, Eisai, Astellas Pharma, Regeneron, RAPT Therapeutics, Geovax Labs, Janssen, Summit Therapeutics Speakers' Bureau: Coherus Biosciences Research Funding (Inst.): Hookipa Biotech, EMD Serono, Purple Biotech, Bristol-Myers Squibb/Celgene, BeiGene, Abbvie, Astellas Pharma, Pfizer, Janux Therapeutics

Observing modern times through ancient eyes with True Life Podcast's, George Monty.

Monty, Micah, and Nick recap the opening weekend of ACC baseball and provide overreactions, including red flags, biggest surprises, and disappointments.

Sermon Notes Date: 02/15/2026 Preacher: Monty Simao, pastor Study: Matthew Key Text: Matthew 1:1-17 Description: What if the most “boring” part of your Bible is actually a blazing announcement that the King has come for people just like you? Today on Scandia Bible Church Podcast, Pastor Monty Simao begins a new study through the Gospel […]

This week on Where's That Bar Cart, we cover two-woman Luge and other happenings at the Winter Olympics, Haymen & Fire Machines, and the first ever TGL hole-in-one which leads us to explaining to Monty (again) the hole-in-one etiquette, to his bafflement. Join us for the first ever Bar Cart Comedy Night on February 22nd, 7:30pm at The Firkin on Yonge, 207 Yonge St.Thanks to Comedy Records and to each and every one of you who listens, watches, and supports our podcast. Please subscribe to our YouTube channel @ComedyRecords. Swing well out there. Follow us at:- @wheresthatbarcart- linkt.ree/wheresthatbarcart- @dpurcomic- @montymofoscott- @nickdurie- @comedyrecordsMusic by Devin BatesonThank you to Comedy Records

In this special episode of Big Crystal Energy, Ashleigh sits down with Kim Charlson, the voice channel behind **Vessel & Voice—and a trans-channel who works closely with her guide, Monty.This conversation is intentionally intuitive and wide-ranging: how Kim first spontaneously voice-channeled, what “channeling” actually means (hint: it's broader than most people realize), why crystals are powerful training tools for discernment, and how to approach the non-physical with groundedness, safety, and sovereignty.If you've been curious about spirit guides, energetic boundaries, or what a channeling session really looks like behind the scenes—this one's for you.In this episode, we cover:What voice channeling is (and how it differs from broader forms of channeling)Kim's first spontaneous channeling experience—and the validation that confirmed it was realWhy many people are “channeling” more often than they think (especially intuitive crystal people)Using crystals as stable energy anchors to build discernment and psychic vocabularyKim shares crystals she worked with early on, including citrine and Isua stone“Light” vs “dark” energetic aesthetics—without the morality overlay (and why preference isn't “bad”)When someone might seek channeling: practical guidance, bigger spiritual questions, new perspectiveThe foundations of safe channeling: grounding, nervous system safety, opening energetic centersWhy movement can be grounding (including ADHD-friendly approaches) and why there's no one “right” methodImportant nuance: not everyone should channel, especially if dissociation is part of someone's mental health pictureGreen flags vs red flags in channeled guidanceEmpowering guidance vs “fear + shoulds + control” energyKim's channeling process with Monty: invocation, verification, Q&A style sessions, and “human tending”The “iracular experience”: when the energy of what you receive shifts you—beyond logic or explanationKim's personal story: from marketing agency hustle, burnout, and a major health crisis… to energy healing and channelingWhy it's never “too late” to begin: your path can open at any age—and often doesMentioned in the episode:Opening the Door (where Ashleigh first heard Kim)Crystals for training/grounding + discernment: citrine, quartz, Isua stone, impactite, petrified palm root, labradorite, smoky quartz (and more)Connect with Kim:Podcast: Vessel & Voice (audio + video on YouTube)Social: @KimCharlson (most platforms)Free “Meet Your Spirit Guides” meditation + mini channeled course on bravery at: kimcharlson.comSend me any questions or comments you may have and I will answer them on upcoming podcast episodes!! Looking forward to hearing from you!Please message me with any questions or comments. bigcrystalenergypodcast @gmail.com

Monty, Micah, and Nick preview every ACC-related matchup on 2026 Opening Weekend. The trio provide their picks for each matchup and select their first Weekend X-Factors of the season.

10am hour of The K&C Masterpiece! Jordan Montgomery is heading back to the Rangers. Our brand-new Olympic segment: Snow far, so good. Baseball Nuggets: The winners, losers and Rangers of MLB's offseason

Monty, Nick, and Micah provide their predictions on a variety of ACC topics ahead of the 2026 college baseball season.

This week, we kick off with a hit of nostalgia involving The Peach Pit and a forgotten 90’s ‘so-bad-it’s-amazing’ hit song. We remember the ridiculous body shaming of Nicole Richie, Monty's failure to commit to MAFS has her feeling left out, and Mel can’t come to terms with her husband’s inability to remember the man at the centre of a shocking 90’s tragedy. We also talk about Victoria's move to allow GPs to treat and diagnose ADHD, Mel shares three batshit crazy stories she heard this week that involve penis injections, periods and a shocking sex stat, as well as a male vs female wee revelation that blew our tiny minds. Enjoy! Fancy supporting us on Patreon? Find out more here. Follow us and get in touch on Instagram here. Follow us on Facebook here.See omnystudio.com/listener for privacy information.

Monty, Micah, and Nick deep-dive preview the 2026 Wake Forest Demon Deacons. They discuss Wake's losses/newcomers, projected rotation/lineups, schedules, and more.

Topics covered in this episode: Command Book App uvx.sh: Install Python tools without uv or Python Ending 15 years of subprocess polling monty: A minimal, secure Python interpreter written in Rust for use by AI Extras Joke Watch on YouTube About the show Sponsored by us! Support our work through: Our courses at Talk Python Training The Complete pytest Course Patreon Supporters Connect with the hosts Michael: @mkennedy@fosstodon.org / @mkennedy.codes (bsky) Brian: @brianokken@fosstodon.org / @brianokken.bsky.social Show: @pythonbytes@fosstodon.org / @pythonbytes.fm (bsky) Join us on YouTube at pythonbytes.fm/live to be part of the audience. Usually Monday at 10am PT. Older video versions available there too. Finally, if you want an artisanal, hand-crafted digest of every week of the show notes in email form? Add your name and email to our friends of the show list, we'll never share it. Michael #1: Command Book App New app from Michael Command Book App is a native macOS app for developers, data scientists, AI enthusiasts and more. This is a tool I've been using lately to help build Talk Python, Python Bytes, Talk Python Training, and many more applications. It's a bit like advanced terminal commands or complex shell aliases, but hosted outside of your terminal. This leaves the terminal there for interactive commands, exploration, short actions. Command Book manages commands like "tail this log while I'm developing the app", "Run the dev web server with true auto-reload", and even "Run MongoDB in Docker with exactly the settings I need" I'd love it if you gave it a look, shared it with your team, and send me feedback. Has a free version and paid version. Build with Swift and Swift UI Check it out at https://commandbookapp.com Brian #2: uvx.sh: Install Python tools without uv or Python Tim Hopper Michael #3: Ending 15 years of subprocess polling by Giampaolo Rodola The standard library's subprocess module has relied on a busy-loop polling approach since the timeout parameter was added to Popen.wait() in Python 3.3, around 15 years ago The problem with busy-polling CPU wake-ups: even with exponential backoff (starting at 0.1ms, capping at 40ms), the system constantly wakes up to check process status, wasting CPU cycles and draining batteries. Latency: there's always a gap between when a process actually terminates and when you detect it. Scalability: monitoring many processes simultaneously magnifies all of the above. + L1/L2 CPU cache invalidations It's interesting to note that waiting via poll() (or kqueue()) puts the process into the exact same sleeping state as a plain time.sleep() call. From the kernel's perspective, both are interruptible sleeps. Here is the merged PR for this change. Brian #4: monty: A minimal, secure Python interpreter written in Rust for use by AI Samuel Colvin and others at Pydantic Still experimental “Monty avoids the cost, latency, complexity and general faff of using a full container based sandbox for running LLM generated code. “ “Instead, it lets you safely run Python code written by an LLM embedded in your agent, with startup times measured in single digit microseconds not hundreds of milliseconds.” Extras Brian: Expertise is the art of ignoring - Kevin Renskers You don't need to master the language. You need to master your slice. Learning everything up front is wasted effort. Experience changes what you pay attention to. I hate fish - Rands (Michael Lopp) Really about productivity systems And a nice process for dealing with email Michael: Talk Python now has a CLI New essay: It's not vibe coding - Agentic engineering GitHub is having a day Python 3.14.3 and 3.13.12 are available Wall Street just lost $285 billion because of 13 markdown files Joke: Silence, current side project!

Monty, Micah, and Nick deep-dive preview the 2026 Virginia Tech Hokies. They discuss Tech's losses/newcomers, projected rotation/lineups, schedules, and more.

Sermon Notes Date: 02/08/2026 Preacher: Josh Peglow, pastor Series: Colossians Key Text: Colossians 3:22 – 4:1 Description: You belong to Christ. Not in part. Not in theory. Not on Sundays. But entirely. And that allegiance reshapes everything — even the places where authority, work, and power intersect. Today on Scandia Bible Church Podcast, Pastor Josh […]

Monty, Micah, and Nick deep-dive preview the 2026 Virginia Cavaliers. They discuss UVA's losses/newcomers, projected rotation/lineups, schedules, and more.

Monty, Micah, and Nick deep-dive preview the 2026 Stanford Cardinal. They discuss Stanford's losses/newcomers, projected rotation/lineups, schedules, and more.

Monty, Micah, and Nick deep-dive preview the 2026 Pittsburgh Panthers. They discuss Pitt's losses/newcomers, projected rotation/lineups, schedules, and more.

Tom Carver was a long-time foreign correspondent with the BBC. He was latterly the BBC's Washington Correspondent and continues to live in Washington working as a writer and consultant. He is the step-grandson of Field Marshal Montgomery. This book would make a great TV series. Get your copy of Where The Hell Have You Been?: Monty, Italy and One Man's Incredible Escape Anthony Scaramucci is the founder and managing partner of SkyBridge, a global alternative investment firm, and founder and chairman of SALT, a global thought leadership forum and venture studio. He is the host of the podcast Open Book with Anthony Scaramucci. A graduate of Tufts University and Harvard Law School, he lives in Manhasset, Long Island. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Monty's plan to swing left has failed. Now he wants Patton's help who still does not trust the British. During this a slight British officer pulls off a miracle. Meanwhile the fighting on Sicily is felt in Rome as Mussolini is voted out of power. Learn more about your ad choices. Visit megaphone.fm/adchoices

This week on Pour Minds, Lex P and Drea Nicole are back with a solo episode — just a kickback with the girls — and it goes from unhinged to deep real quick. They start off debating the afterlife and reincarnation (because imagine coming back as a roach??) and spiral into questions nobody can answer: what do we look like when we cross over, do we get signs from loved ones, and do we really come back as somebody—or something—else? The girls also catch up on life updates, gym routines, sleep schedules, and Lex learning the hard way that being “too honest” on the internet will have folks dragging your name for fun. From raggedy car jokes to people tagging you in wild stuff, they talk about setting boundaries with fans, not letting strangers get too comfortable, and why blocking is self-care in 2026.Then they get into a bigger conversation: are people addicted to being offended? Lex and Drea break down rage bait culture, cancel culture, and why folks love acting morally superior online — even when they don’t keep that same energy in real life. Plus, The Bed (brought to you by Salt.xo) gets spicy with hookup etiquette: don’t ghost, wrap it up, be honest about other partners, and for the love of God… don’t be doing mouth-spit activities with a hookup like it’s a committed relationship.See omnystudio.com/listener for privacy information.

Monty's 8th Army can't push on north to Catania, so he has other forces swing to the left. But this 3 prong attack fails as well. Ordering his men to go on the defensive, Monty calls in more troops from North Africa. Meanwhile, Patton is planning his drive east, to Messina. Learn more about your ad choices. Visit megaphone.fm/adchoices